Perceptive Informatics® Global Survey Results Indicate Growing Demand for CTMS to Assist in More Efficient Site Monitoring

Perceptive Informatics® Global Survey Results Indicate Growing Demand for CTMS to Assist in More Efficient Site Monitoring and Management

BOSTON, May 19, 2011 /PRNewswire/ -- Perceptive Informatics, the industry's leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced results of a global survey conducted during its webinar entitled "Critical Tasks of Site Monitors: Using a CTMS to Improve Efficiency." Perceptive polled biopharmaceutical industry professionals across a broad range of clinical, data management and IT functions about the value of providing Clinical Research Associates (CRAs) with access to a Clinical Trial Management System (CTMS) to assist in site monitoring and management activities during clinical trials.

The survey results revealed that 89% of respondents provide CRAs with access to either a CTMS or other monitoring tool. The majority of these respondents combine other monitoring tools with a CTMS to achieve greater site monitoring and management efficiencies. A CTMS helps CRAs to view the status of a clinical trial, access patient data, and identify outstanding issues, as well as to make informed decisions about requirements for site visits. The remaining respondents (11%) provide no access to these types of systems.

"As site management is a key part of the CRA role, providing CRAs with access to the cross-study and cross-site data available within a CTMS is vital. There is growing recognition across the industry that when CRAs use sophisticated eClinical technologies they are more efficient in site monitoring and management activities," said Liz Love, Product Manager of CTMS, Perceptive Informatics. "At Perceptive, we are focused on enabling more effective centralized and field-based monitoring through our CTMS to support an increasingly mobile and globalized CRA workforce."

The IMPACT® MySites™ module, which is part of the IMPACT CTMS from Perceptive Informatics, is a complete site management and monitoring tool. The MySites module provides a view of key milestones, recruitment progress, and issue activity across all sites, allowing CRAs to seamlessly monitor workload and plan site visits, whether they are working online or offline. The IMPACT CTMS from Perceptive Informatics, an enterprise-wide solution used to plan, track, and report on clinical trials, is available as a hosted, software-as-a-service (SaaS) application and is part of the Perceptive Informatics eClinical Suite. About Perceptive Informatics

Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. Perceptive enables customers to maximize the benefits of clinical trial technologies by providing flexible software-as-a-service (SaaS) applications and leading technology services. The Perceptive Informatics eClinical Suite is built on extensive medical and clinical expertise, as well as a deep understanding of the regulatory environment. The suite includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO).  The Perceptive Informatics eClinical Suite blurs the boundaries among systems that traditionally have been used in isolation, resulting in simplified workflow, improved efficiency and enhanced productivity. For more information about the integrated solutions in the Perceptive Informatics eClinical Suite visit www.perceptive.com.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,350 employees. For more information about PAREXEL International visit www.PAREXEL.com.

 

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.